Last quarter (Q1 2025), BriaCell Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q1, BriaCell Therapeutics's net income was $-5.80M. See BriaCell Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Jul 24	Jul 23	Jul 22	Jul 21
Total Revenue	$ ―	$ ―	$ ―	$ ―	$ ―
Cost of Revenue	$ ―	$ ―	$ ―	$ ―	$ ―
Gross Profit	$ ―	$ ―	$ ―	$ ―	$ ―
Operating Expense	$ 29.98M	$ 33.33M	$ 23.27M	$ 15.29M	$ 6.97M
Operating Income	$ -29.98M	$ -33.33M	$ -23.27M	$ -15.29M	$ -6.97M
Net Non Operating Interest Income Expense	$ 371.48K	$ 550.58K	$ 891.21K	$ -137.71K	$ 4.52M
Other Income Expense	$ -13.17M	$ -28.14M	$ -2.12M	$ 11.66M	$ -2.32M
Pretax Income	$ -16.46M	$ -4.67M	$ -20.30M	$ -27.12M	$ -13.82M
Tax Provision	$ ―	$ ―	$ ―	$ ―	$ ―
Earnings From Equity Interest Net Of Tax	$ -178.03K	$ -106.51K	$ ―	$ ―	$ ―
Net Income Common Stockholders	$ -16.33M	$ -4.53M	$ -20.30M	$ -27.12M	$ -13.82M
Basic EPS	$ -0.87	$ -0.29	$ -1.30	$ -1.73	$ -3.06
Diluted EPS	$ -0.88	$ -0.29	$ -1.30	$ -1.73	$ -3.06
Basic Average Shares	$ 76.48M	$ 16.45M	$ 15.62M	$ 15.49M	$ 4.52M
Diluted Average Shares	$ 75.79M	$ 16.45M	$ 15.62M	$ 15.49M	$ 4.52M
Dividend Per Share	$ ―	$ ―	$ ―	$ ―	$ ―
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―	$ ―
Total Expenses	$ 29.98M	$ 33.33M	$ 23.27M	$ 15.29M	$ -6.97M
Net Income From Continuing And Discontinued Operation	$ -16.33M	$ -4.53M	$ -20.30M	$ -27.12M	$ -13.82M
Normalized Income	$ -16.29M	$ -4.62M	$ -14.92M	$ -19.93M	$ -10.01M
Interest Expense	$ ―	$ ―	$ ―	$ ―	$ ―
EBIT	$ -16.46M	$ -4.67M	$ -20.30M	$ -27.12M	$ -13.74M
EBITDA	$ -16.35M	$ -4.59M	$ -20.29M	$ -27.10M	$ -13.72M

Currency in USD

BriaCell Therapeutics Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing